

# Chung-Han Lee

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/244380/publications.pdf>

Version: 2024-02-01

71  
papers

5,417  
citations

257357

24  
h-index

143943

57  
g-index

74  
all docs

74  
docs citations

74  
times ranked

9531  
citing authors

#	ARTICLE	IF	CITATIONS
1	Tumor mutational load predicts survival after immunotherapy across multiple cancer types. <i>Nature Genetics</i> , 2019, 51, 202-206.	9.4	2,702
2	An Integrated Metabolic Atlas of Clear Cell Renal Cell Carcinoma. <i>Cancer Cell</i> , 2016, 29, 104-116.	7.7	531
3	Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2020, 38, 1154-1163.	0.8	276
4	mTOR Pathway as a Target in Tissue Hypertrophy. <i>Annual Review of Pharmacology and Toxicology</i> , 2007, 47, 443-467.	4.2	162
5	Constitutive mTOR activation in TSC mutants sensitizes cells to energy starvation and genomic damage via p53. <i>EMBO Journal</i> , 2007, 26, 4812-4823.	3.5	153
6	Update on Tumor Neoantigens and Their Utility: Why It Is Good to Be Different. <i>Trends in Immunology</i> , 2018, 39, 536-548.	2.9	152
7	Prevalence of Germline Mutations in Cancer Susceptibility Genes in Patients With Advanced Renal Cell Carcinoma. <i>JAMA Oncology</i> , 2018, 4, 1228.	3.4	132
8	Lenvatinib plus pembrolizumab in patients with either treatment-naïve or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study. <i>Lancet Oncology</i> , The, 2021, 22, 946-958.	5.1	100
9	A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma. <i>Oncologist</i> , 2016, 21, 787-788d.	1.9	84
10	Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin. <i>Journal of Clinical Investigation</i> , 2016, 126, 3526-3540.	3.9	82
11	Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non-“Clear-Cell Renal Cell Carcinoma and Genomic Correlates. <i>Journal of Clinical Oncology</i> , 2022, 40, 2333-2341.	0.8	72
12	Phase II Trial and Correlative Genomic Analysis of Everolimus Plus Bevacizumab in Advanced Non-“Clear Cell Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 3846-3853.	0.8	69
13	A systematic review of predictive and prognostic biomarkers for VEGF-targeted therapy in renal cell carcinoma. <i>Cancer Treatment Reviews</i> , 2014, 40, 533-547.	3.4	61
14	Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 1-6.	0.9	60
15	Comprehensive Molecular Characterization and Response to Therapy in Fumarate Hydratase-“Deficient Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 2910-2919.	3.2	45
16	Circulating biomarkers and outcome from a randomised phase II trial of sunitinib vs everolimus for patients with metastatic renal cell carcinoma. <i>British Journal of Cancer</i> , 2016, 114, 642-649.	2.9	43
17	Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 1312-1322.	0.8	42
18	Metastatic Chromophobe Renal Cell Carcinoma: Presence or Absence of Sarcomatoid Differentiation Determines Clinical Course and Treatment Outcomes. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e678-e688.	0.9	41

#	ARTICLE	IF	CITATIONS
19	Genomic Characterization of Renal Medullary Carcinoma and Treatment Outcomes. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e987-e994.	0.9	39
20	DNA damage repair pathway alterations in metastatic clear cell renal cell carcinoma and implications on systemic therapy. , 2020, 8, e000230.		37
21	Immune Checkpoint Therapy in Renal Cell Carcinoma. <i>Cancer Journal (Sudbury, Mass )</i> , 2016, 22, 92-95.	1.0	35
22	Tumor Xenografts of Human Clear Cell Renal Cell Carcinoma But Not Corresponding Cell Lines Recapitulate Clinical Response to Sunitinib: Feasibility of Using Biopsy Samples. <i>European Urology Focus</i> , 2017, 3, 590-598.	1.6	31
23	Lenvatinib + pembrolizumab in patients with renal cell carcinoma: Updated results.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4560-4560.	0.8	30
24	Comparative Genomic Profiling of Matched Primary and Metastatic Tumors in Renal Cell Carcinoma. <i>European Urology Focus</i> , 2018, 4, 986-994.	1.6	29
25	Mucinous Tubular and Spindle-Cell Carcinoma of the Kidney: Clinical Features, Genomic Profiles, and Treatment Outcomes. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 268-274.e1.	0.9	29
26	New approaches to first-line treatment of advanced renal cell carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110347.	1.4	25
27	Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial. <i>Clinical Cancer Research</i> , 2021, 27, 6687-6695.	3.2	25
28	Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial. <i>Clinical Cancer Research</i> , 2022, 28, 3248-3255.	3.2	24
29	Everolimus plus bevacizumab is an effective first-line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial. <i>Cancer</i> , 2020, 126, 5247-5255.	2.0	22
30	Phase II Study of Neoadjuvant Nivolumab in Patients with Locally Advanced Clear Cell Renal Cell Carcinoma Undergoing Nephrectomy. <i>European Urology</i> , 2022, 81, 570-573.	0.9	22
31	Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma. <i>European Urology</i> , 2020, 78, 907-915.	0.9	21
32	High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab. <i>Molecular Cancer Research</i> , 2021, 19, 1510-1521.	1.5	20
33	The evolution of anti-angiogenic therapy for kidney cancer. <i>Nature Reviews Nephrology</i> , 2017, 13, 69-70.	4.1	19
34	<i>ALK</i> Fusions in Renal Cell Carcinoma: Response to Entrectinib. <i>JCO Precision Oncology</i> , 2018, 2, 1-8.	1.5	16
35	Treatment of Metastatic Prostate Cancer in 2018. <i>JAMA Oncology</i> , 2019, 5, 263.	3.4	16
36	Germline Variants Identified in Patients with Early-onset Renal Cell Carcinoma Referred for Germline Genetic Testing. <i>European Urology Oncology</i> , 2021, 4, 993-1000.	2.6	16

#	ARTICLE	IF	CITATIONS
37	The current role for adjuvant and neoadjuvant therapy in renal cell cancer. <i>Current Opinion in Urology</i> , 2019, 29, 636-642.	0.9	12
38	Systemic therapy for advanced clear cell renal cell carcinoma after discontinuation of immune-oncology and VEGF targeted therapy combinations. <i>BMC Urology</i> , 2020, 20, 84.	0.6	12
39	Prevalence and Landscape of Actionable Genomic Alterations in Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 5595-5606.	3.2	12
40	Genomic and Metabolic Hallmarks of SDH- and FH-deficient Renal Cell Carcinomas. <i>European Urology Focus</i> , 2022, 8, 1278-1288.	1.6	11
41	Correlative serum biomarker analyses in the phase 2 trial of lenvatinib-plus-everolimus in patients with metastatic renal cell carcinoma. <i>British Journal of Cancer</i> , 2021, 124, 237-246.	2.9	10
42	Pretreatment Eosinophil Counts in Patients With Advanced or Metastatic Urothelial Carcinoma Treated With Anti-PD-1/PD-L1 Checkpoint Inhibitors. <i>Journal of Immunotherapy</i> , 2021, 44, 248-253.	1.2	10
43	A phase II trial of durvalumab and tremelimumab in metastatic, non-urothelial carcinoma of the urinary tract. <i>Cancer Medicine</i> , 2021, 10, 1074-1083.	1.3	10
44	Persistent Severe Hyperlactatemia and Metabolic Derangement in Lethal <i>SDHB</i> -Mutated Metastatic Kidney Cancer: Clinical Challenges and Examples of Extreme Warburg Effect. <i>JCO Precision Oncology</i> , 2017, 1, 1-14.	1.5	9
45	Personalizing First-Line Management of Metastatic Renal Cell Carcinoma: Leveraging Current and Novel Therapeutic Options. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, , 1-9.	2.3	8
46	Sunitinib as a paradigm for tyrosine kinase inhibitor development for renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 275-279.	0.8	7
47	Bevacizumab Monotherapy as Salvage Therapy for Advanced Clear Cell Renal Cell Carcinoma Pretreated With Targeted Drugs. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 56-62.	0.9	7
48	Comprehensive Genomic Analysis of Metastatic Non-Clear-Cell Renal Cell Carcinoma to Identify Therapeutic Targets. <i>JCO Precision Oncology</i> , 2019, 3, 1-18.	1.5	7
49	Combination VEGFR/immune checkpoint inhibitor therapy: a promising new treatment for renal cell carcinoma. <i>British Journal of Cancer</i> , 2018, 119, 911-912.	2.9	6
50	Everolimus (E) plus bevacizumab (B) is effective first-line treatment for patients (pts) with advanced renal cell carcinoma (RCC) with papillary features (PF): Results from a phase II trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 627-627.	0.8	6
51	In silico modeling of combination systemic therapy for advanced renal cell carcinoma. , 2021, 9, e004059.		5
52	Molecular Characterization of the Tumor Microenvironment in Renal Medullary Carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
53	Combination therapy for advanced and metastatic kidney cancer. <i>Nature Reviews Urology</i> , 2019, 16, 77-78.	1.9	3
54	Systemic therapy for advanced clear cell renal cell carcinoma (ccRCC) after progression on immune-oncology plus VEGF targeted therapy combinations (IO-VEGF).. <i>Journal of Clinical Oncology</i> , 2019, 37, 4576-4576.	0.8	3

#	ARTICLE	IF	CITATIONS
55	Medullary renal cell carcinoma (RCC): Genomics and treatment outcomes.. Journal of Clinical Oncology, 2016, 34, 4556-4556.	0.8	3
56	Matched Molecular Profiling of Cell-Free DNA and Tumor Tissue in Patients With Advanced Clear Cell Renal Cell Carcinoma. JCO Precision Oncology, 2022, , .	1.5	3
57	Quality-adjusted Time Without Symptoms or Toxicity (Q-TWiST) for Lenvatinib plus Everolimus Versus Everolimus Monotherapy in Patients with Advanced Renal Cell Carcinoma. European Urology Open Science, 2021, 31, 1-9.	0.2	2
58	MP35-19 SORBITOL AS A NOVEL MECHANISM OF HYPOXIA-INDUCIBLE FACTOR (HIF) PATHWAY ACTIVATION IN CLEAR CELL PAPILLARY RENAL CELL CARCINOMA (CCPRCC). Journal of Urology, 2014, 191, .	0.2	1
59	PBRM1: A Critical Subunit of the SWI/SNF Chromatin Remodeling Complex. , 2015, , 111-151.		1
60	The genomic landscape of metastatic non-clear cell renal cell carcinoma.. Journal of Clinical Oncology, 2017, 35, 474-474.	0.8	1
61	Discovery and prevalence of cancer-susceptibility germline mutations (Mts) in patients (Pts) with advanced renal cell carcinoma (aRCC).. Journal of Clinical Oncology, 2017, 35, 4524-4524.	0.8	1
62	From molecular understanding to clinical advances. Nature Reviews Urology, 2014, 11, 77-79.	1.9	0
63	Global metabolic profiling of clear cell renal cell carcinoma.. Journal of Clinical Oncology, 2013, 31, 379-379.	0.8	0
64	Src pathway activation in RCC and the correlation with grade and survival and the development of a rational new target in RCC.. Journal of Clinical Oncology, 2014, 32, 453-453.	0.8	0
65	Bevacizumab monotherapy as salvage therapy for patients with advanced clear cell renal cell carcinoma pretreated with targeted drugs.. Journal of Clinical Oncology, 2015, 33, 468-468.	0.8	0
66	Novel chromosome copy number changes to predict clinical response to sunitinib in patients with advanced renal cell carcinoma.. Journal of Clinical Oncology, 2015, 33, 4552-4552.	0.8	0
67	Metastasis-associated mutations in clear cell renal cell carcinoma.. Journal of Clinical Oncology, 2016, 34, 600-600.	0.8	0
68	Genomic and metabolic characterization of succinate dehydrogenase B deficient renal cell carcinoma.. Journal of Clinical Oncology, 2016, 34, e16102-e16102.	0.8	0
69	Clinical and genomic alternations predictive of response to sunitinib in patients with advanced renal cell carcinoma.. Journal of Clinical Oncology, 2016, 34, e16109-e16109.	0.8	0
70	Outcomes of metastatic chromophobe renal cell carcinoma (ChRCC) with sarcomatoid features (SF).. Journal of Clinical Oncology, 2018, 36, 678-678.	0.8	0
71	Single-center analysis of 109 patients (pts) with metastatic chromophobe renal cell carcinoma (ChRCC): Differences in outcomes by histologic variant.. Journal of Clinical Oncology, 2018, 36, 4577-4577.	0.8	0